[Atrial fibrillation, comorbidities and new anticoagulants]

Geriatr Psychol Neuropsychiatr Vieil. 2013 Dec;11(1 Suppl):10-6. doi: 10.1684/pnv.2013.0447.
[Article in French]

Abstract

The atrial fibrillation (AF) is one of the most important cause of arythmia and cerebrovascular disease in clinical practice. Comorbidity is defined as the association of active chronical diseases and a target disease.

Method: comparison between burden illness of the patients in interventional (n=4) and observational studies, form Medline database (n=4), was performed.

Results: the level of comorbidity tend to be higher in patients from interventional than large observational studies.

Discussion: in interventional studies, the level cerebro-vascular risk was calculated to compare interventional and control groups. So contrary to what was expected the patients of the general population who can receive anticoagulants have a lesser burden of illness. A recent paper studying new anticoagulants in general population finds this difference again, and would indicate that the risk related to the use of new anticoagulants would not be upper to that observed in the princeps pivotal studies.

Keywords: anticoagulant; atrial fibrillation; comorbidity; elderly; older.

Publication types

  • Comparative Study
  • English Abstract
  • Review

MeSH terms

  • Aged
  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use*
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / epidemiology*
  • Chronic Disease / epidemiology
  • Comorbidity
  • Cost of Illness
  • Drugs, Investigational / adverse effects
  • Drugs, Investigational / therapeutic use*
  • Humans
  • Intracranial Embolism / epidemiology
  • Intracranial Embolism / prevention & control*
  • Observational Studies as Topic
  • Stroke / epidemiology
  • Stroke / prevention & control*

Substances

  • Anticoagulants
  • Drugs, Investigational